Not a good buy right now for an impatient trader: technicals are still bearish and there are no near-term catalysts/news to drive a clean breakout.
Price is hovering just above key support (S1 ~7.115) with bearish momentum; odds favor choppy/fragile action rather than a sustained move up.
Hedge funds have been accumulating (+162% QoQ), and UBS initiated Buy with a $20 PT, but those are longer-horizon signals vs. an immediate entry setup.
Trend/Momentum: MACD histogram is negative (-0.0773) and negatively expanding → downside momentum remains in control.
RSI: RSI_6 at ~21 suggests the stock is deeply oversold (near-term bounce potential), but oversold can persist in weak trends.
Moving averages: converging MAs → no clear trend reversal confirmation yet.
Key levels: Support S1 ~7.115 (price ~7.24 pre-market is just above it); next support S2 ~6.60. Resistance/pivot ~7.948; R1 ~8.78.
Pattern-based probability: near-term slightly positive (next day/week), but next-month expectation is negative (-1.33%) → rallies may fade without a catalyst.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Put/call ratios at 0.0 (based on provided fields) imply skewed/limited put activity in the dataset; however, many core fields (OI, volume, IV) are blank, so sentiment read-through is low confidence.
Historical volatility is extremely high (~122%), consistent with a small-cap biotech where price can move sharply without warning—better for tactical trades only when signals align (not the case today).
Technical Summary
Sell
8
Buy
4
Positive Catalysts
near support can produce a reflex bounce if buyers defend ~7.11.
Neutral/Negative Catalysts
No news in the recent week → no obvious event-driven catalyst to force a sustained upside move.
Bearish momentum: MACD negative and expanding lower suggests sellers still control the tape.
Financial trend: revenue declined sharply YoY and losses remain sizable, typical of higher-risk biotech setups.
Lack of proprietary trade timing help: no AI Stock Picker or SwingMax entry today.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $0.741M, down -41.61% YoY → top-line weakness.
Net income: -$31.54M, improved +63.75% YoY (loss narrowed), but still materially negative.
EPS: -3.04, worsened YoY (more negative by 0.98) → profitability still deteriorated on a per-share basis.
Gross margin: 100% (flat) — not very informative at this scale; the main story is cash burn/ongoing losses.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: UBS (2026-01-07) initiated coverage with a Buy rating and a $20 price target.
Wall Street pro view (pros): biotech fundamentals “inflecting,” potential 2026 recovery theme; initiation suggests perceived upside optionality.
Wall Street con view (cons): only one recent data point provided (limited consensus visibility); without near-term catalysts/news, the stock may not re-rate quickly despite a high target.
Influential/political trading: no recent congress trading data available; insiders reported neutral (no significant recent trend).
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 81.67 USD with a low forecast of 20 USD and a high forecast of 175 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 81.67 USD with a low forecast of 20 USD and a high forecast of 175 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.490
Low
20
Averages
81.67
High
175
Current: 6.490
Low
20
Averages
81.67
High
175
UBS
Michael Yee
Buy
initiated
$20
AI Analysis
2026-01-07
Reason
UBS
Michael Yee
Price Target
$20
AI Analysis
2026-01-07
initiated
Buy
Reason
UBS analyst Michael Yee initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $20 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
H.C. Wainwright
initiated
$50
2025-08-18
Reason
H.C. Wainwright
Price Target
$50
2025-08-18
initiated
Reason
H.C. Wainwright assumed coverage of Aligos Therapeutics with a Buy rating and $50 price target. The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALGS
